Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac + serratiopeptidase is a fixed-dose combination therapy used for the treatment of pain and inflammation. Diclofenac is a non-selective nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which are responsible for the production of prostaglandins that mediate pain, fever, and inflammation. Serratiopeptidase is a proteolytic enzyme that aids in the reduction of inflammation and edema by breaking down fibrin and other proteins associated with the inflammatory response, as well as by thinning the fluids formed during inflammation to facilitate their drainage. This combination is particularly effective in managing postoperative swelling and traumatic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + serratiopeptidase.